Microreview

Abstract

Researchers are recently proposing that the best way to fight a disease may just be to alter our genes. Gene therapy could be the new method for fighting large B-cell lymphoma. The newly discovered CAR-T therapy (chimeric antigen receptor T-cell therapy) is the first gene therapy to be approved by the FDA. There are currently two-products available on the market, tisagenlecleucel and axicabtagene ciloleucel. While this treatment has only been used on patients that are nonresponsive to any of the normal treatments, there has been an overall success.  Even with these remarkable results, there are still problems that arise. First, treatment is very expensive due to the extensive testing. Also, there are various unpredictable side effects that researchers are not clear on the origin of. Lastly, precision in therapy delivery is a rising problem. Researchers are searching for cheaper and safer ways to test and modify genes. While the side effects are unpredictable, researchers have found them to be treatable.  Since these trials have had substantial results compared to others and considering how fast CAR-T therapy has progressed, it is becoming well recognized and trusted treatment method.